Axilum Robotics

Axilum Robotics specializes in developing robotic systems for transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique. The company's flagship product, the TMS Robot, is designed to automate the TMS process, which is traditionally performed manually. This automation enhances the accuracy, repeatability, and safety of the procedure, making it a valuable tool for clinical services and research. Axilum Robotics operates in the medical device market, serving healthcare providers and research institutions that require precise and efficient TMS administration. The business model is centered around the sale and distribution of its robotic systems, which have received CE marking in Europe and FDA 510k clearance in the USA, ensuring compliance with international safety standards. The company generates revenue through the direct sale of its devices and potentially through service agreements for maintenance and support. Axilum Robotics' technology allows operators to maintain a safe distance from patients, a feature that gained particular relevance during the COVID-19 pandemic. This capability not only improves safety but also facilitates the training of participants to perform certain tasks independently, further enhancing the efficiency of TMS procedures.

Keywords: transcranial magnetic stimulation, robotic automation, medical device, TMS Robot, healthcare, brain stimulation, safety, precision, clinical services, FDA clearance.